Improving heart and kidney treatment for patients with diabetes
Closing the Cardio-Renal Preventive Treatment Gap Among Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease: An Implementation Science Approach
This study is looking into why people with type 2 diabetes and chronic kidney disease aren't getting the heart-protecting treatments they need, and it aims to find ways to make sure these important medications are prescribed more often.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11015914 on NIH RePORTER |
What this research studies
This research investigates why patients with type 2 diabetes and chronic kidney disease are not receiving effective treatments that can prevent cardiovascular disease. By analyzing a large dataset of over 1.5 million patients and conducting focus groups with both patients and healthcare providers, the study aims to identify barriers to the prescription of essential therapies. The goal is to understand the factors that contribute to the under-prescription of these life-saving medications and to develop strategies to improve their use in clinical practice.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with type 2 diabetes mellitus and chronic kidney disease.
Not a fit: Patients without diabetes or kidney disease, or those who are not at risk for cardiovascular disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better management of cardiovascular risks in patients with diabetes and chronic kidney disease, ultimately improving their health outcomes.
How similar studies have performed: Previous research has shown that addressing barriers to medication adherence can significantly improve patient outcomes, suggesting that this approach may also be effective.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Lamprea Montealegre, Julio Alejandro — University of California, San Francisco
- Study coordinator: Lamprea Montealegre, Julio Alejandro
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.